title: The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study.
abstract: The revised 2007 American Thoracic Society/Infectious Diseases Society of America statement recommend clarithromycin-based combination therapy for treatment of Mycobacterium avium complex lung disease and stipulates approximately 1 year of continuous treatment after bacilli negative conversion. However, supporting data are insufficient. Our objective was to obtain data on the clinical outcome of clarithromycin-based daily regimens by conducting a nationwide retrospective post-marketing study of M. avium complex lung disease. In accordance with the Japanese guidelines, patients were enrolled in this survey according to their chest radiographic findings and microbiologic test results. They were treated with a multidrug regimen including clarithromycin, rifampicin, and ethambutol (clarithromycin-based regimen) until bacilli negative conversion, and the treatment was continued for approximately 1 year after the initial conversion. Data were collected before administration, at the time of bacilli negative conversion, at the end of treatment, and at 6 months after the end of treatment. Of the 466 subjects enrolled in the study, 271 patients who received clarithromycin at 800 mg/day underwent evaluation for M. avium complex disease. The final bacilli negative conversion rate in those patients was 94.7%. The bacteriological relapse rate was 5.0% (5/100 patients). Bacteriological relapse was noted in patients treated for less than 15 months after conversion. No life-threatening or serious adverse drug reactions were observed. This study demonstrated that a clarithromycin-based daily regimen can yield a high bacteriological conversion rate in M. avium complex disease. After conversion, treatment for less than 15 months might be insufficient to prevent bacteriological relapse.
authors.affiliation: Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan. Electronic address: kadota@oita-u.ac.jp.
authors.forename: Jun-Ichi
authors.initials: JI
authors.lastname: Kadota
authors.affiliation: Respiratory Medicine Division, Respiratory Diseases Center Fukujuji Hospital, Tokyo, Japan.
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Kurashima
authors.affiliation: National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use*; D004359:Drug Therapy, Combination / Q000379:methods; D004977:Ethambutol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000382:microbiology*; D008297:Male; D040541:Marketing / Q000379:methods; D015269:Mycobacterium avium Complex / Q000187:drug effects*; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D012189:Retrospective Studies; D012293:Rifampin / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents; D004977:Ethambutol; D017291:Clarithromycin; D012293:Rifampin
keywords: Bacilli negative conversion rate; Clarithromycin; Mycobacterium avium complex; Post-marketing study; Relapse